FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1907921133> ?p ?o ?g. }

• W1907921133 endingPage "1087" @default.
• W1907921133 startingPage "1083" @default.
• W1907921133 abstract "Randomized controlled trials have shown that rituximab is non-inferior to cyclophosphamide followed by azathioprine (CYC/AZA) for remission induction in severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The efficacy of rituximab is on par with CYC/AZA for 18 months, for patients with GPA and MPA alike, and for patients with any degree of renal impairment. The Rituximab in ANCA-associated Vasculitis (RAVE) trial also showed superiority of rituximab for patients presenting with a severe disease relapse. An exploratory analysis of the RAVE data further suggests that rituximab may be preferable for PR3-ANCA-positive patients as superiority was also achieved in that subset. When considering treatment options for patients with disease presentations for which only non-inferiority has been documented, safety concerns, compliance issues, the overall cost of each treatment approach to the patient, to society and to insurers, as well as individual patient preferences all should affect the decision-making process. The trials failed to uncover any difference in adverse events between rituximab and CYC/AZA. However, daily oral cyclophosphamide given for 3-6 months has measurable negative effects on fertility. Rituximab has certain compliance and convenience advantages. When assessing cost, the overall cost of a treatment, the societal context of the individual patient and not merely the sticker price of the drug should be considered. For all of these reasons, the author believes that CYC/AZA should be reserved for patients with newly diagnosed, MPO-ANCA-positive disease who raise no fertility, compliance or malignancy concerns." @default.
• W1907921133 created "2016-06-24" @default.
• W1907921133 creator A5012967877 @default.
• W1907921133 date "2015-05-21" @default.
• W1907921133 modified "2023-10-18" @default.
• W1907921133 title "Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?" @default.
• W1907921133 cites W1824049500 @default.
• W1907921133 cites W1914343637 @default.
• W1907921133 cites W1964913193 @default.
• W1907921133 cites W1972087622 @default.
• W1907921133 cites W1979398789 @default.
• W1907921133 cites W1990393482 @default.
• W1907921133 cites W2000948923 @default.
• W1907921133 cites W2007778318 @default.
• W1907921133 cites W2011557149 @default.
• W1907921133 cites W2025060860 @default.
• W1907921133 cites W2036292718 @default.
• W1907921133 cites W2046059252 @default.
• W1907921133 cites W2057194530 @default.
• W1907921133 cites W2063340779 @default.
• W1907921133 cites W2065132929 @default.
• W1907921133 cites W2071782320 @default.
• W1907921133 cites W2080428274 @default.
• W1907921133 cites W2080721448 @default.
• W1907921133 cites W2084056567 @default.
• W1907921133 cites W2100809783 @default.
• W1907921133 cites W2104511883 @default.
• W1907921133 cites W2104585211 @default.
• W1907921133 cites W2119900188 @default.
• W1907921133 cites W2125981561 @default.
• W1907921133 cites W2126583107 @default.
• W1907921133 cites W2132820210 @default.
• W1907921133 cites W2138612272 @default.
• W1907921133 cites W2138672810 @default.
• W1907921133 cites W2140729034 @default.
• W1907921133 cites W2163003110 @default.
• W1907921133 cites W2171643265 @default.
• W1907921133 cites W249810009 @default.
• W1907921133 doi "https://doi.org/10.1093/ndt/gfv217" @default.
• W1907921133 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4479669" @default.
• W1907921133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25999375" @default.
• W1907921133 hasPublicationYear "2015" @default.
• W1907921133 type Work @default.
• W1907921133 sameAs 1907921133 @default.
• W1907921133 citedByCount "14" @default.
• W1907921133 countsByYear W19079211332015 @default.
• W1907921133 countsByYear W19079211332016 @default.
• W1907921133 countsByYear W19079211332017 @default.
• W1907921133 countsByYear W19079211332019 @default.
• W1907921133 countsByYear W19079211332020 @default.
• W1907921133 countsByYear W19079211332023 @default.
• W1907921133 crossrefType "journal-article" @default.
• W1907921133 hasAuthorship W1907921133A5012967877 @default.
• W1907921133 hasBestOaLocation W19079211332 @default.
• W1907921133 hasConcept C126322002 @default.
• W1907921133 hasConcept C141071460 @default.
• W1907921133 hasConcept C177713679 @default.
• W1907921133 hasConcept C197934379 @default.
• W1907921133 hasConcept C203014093 @default.
• W1907921133 hasConcept C24040308 @default.
• W1907921133 hasConcept C2776015282 @default.
• W1907921133 hasConcept C2776694085 @default.
• W1907921133 hasConcept C2776755627 @default.
• W1907921133 hasConcept C2776760755 @default.
• W1907921133 hasConcept C2778375690 @default.
• W1907921133 hasConcept C2778910314 @default.
• W1907921133 hasConcept C2779134260 @default.
• W1907921133 hasConcept C2779338263 @default.
• W1907921133 hasConcept C2779399171 @default.
• W1907921133 hasConcept C2780653079 @default.
• W1907921133 hasConcept C2781229154 @default.
• W1907921133 hasConcept C71924100 @default.
• W1907921133 hasConceptScore W1907921133C126322002 @default.
• W1907921133 hasConceptScore W1907921133C141071460 @default.
• W1907921133 hasConceptScore W1907921133C177713679 @default.
• W1907921133 hasConceptScore W1907921133C197934379 @default.
• W1907921133 hasConceptScore W1907921133C203014093 @default.
• W1907921133 hasConceptScore W1907921133C24040308 @default.
• W1907921133 hasConceptScore W1907921133C2776015282 @default.
• W1907921133 hasConceptScore W1907921133C2776694085 @default.
• W1907921133 hasConceptScore W1907921133C2776755627 @default.
• W1907921133 hasConceptScore W1907921133C2776760755 @default.
• W1907921133 hasConceptScore W1907921133C2778375690 @default.
• W1907921133 hasConceptScore W1907921133C2778910314 @default.
• W1907921133 hasConceptScore W1907921133C2779134260 @default.
• W1907921133 hasConceptScore W1907921133C2779338263 @default.
• W1907921133 hasConceptScore W1907921133C2779399171 @default.
• W1907921133 hasConceptScore W1907921133C2780653079 @default.
• W1907921133 hasConceptScore W1907921133C2781229154 @default.
• W1907921133 hasConceptScore W1907921133C71924100 @default.
• W1907921133 hasFunder F4320337355 @default.
• W1907921133 hasIssue "7" @default.
• W1907921133 hasLocation W19079211331 @default.
• W1907921133 hasLocation W19079211332 @default.
• W1907921133 hasLocation W19079211333 @default.
• W1907921133 hasLocation W19079211334 @default.
• W1907921133 hasOpenAccess W1907921133 @default.
• W1907921133 hasPrimaryLocation W19079211331 @default.

• next